SCHEMBL899153

SCHEMBL899153

Cc1cc(NCCN(C)C)c2ccccc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 1.00
SLC2A1 P11166 2/20 0.71
CYP2C19 P33261 1/20 0.68
POLB P06746 3/20 0.63
RAD52 P43351 3/20 0.63
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.63
ACP1 P24666 1/20 0.62
TOP2A P11388 2/20 0.55
OPRK1 P41145 1/20 0.53
HTT P42858 1/20 0.53
SMARCA2 P51531 1/20 0.52
NPC1 O15118 1/20 0.51
APOBEC3A P31941 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
APOBEC3G Q9HC16 1/20 0.51
TLR9 Q9NR96 1/20 0.51
PABPC1 P11940 1/20 0.49
EIF4H Q15056 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23029669 0.92 NCF1 (0.84) NCF1SLC2A1CYP2C19POLBRAD52
SCHEMBL4632937 0.85 NCF1 (0.73) NCF1SLC2A1CYP2C19POLBRAD52
Quindecamine SCHEMBL2111177 0.83 CYP2C19 (0.73) NCF1SLC2A1CYP2C19OPRK1
SCHEMBL22390054 0.83 CYP2C19 (0.73) NCF1SLC2A1CYP2C19OPRK1
SCHEMBL12402667 0.83 SLC2A1 (1.00) NCF1SLC2A1POLBRAD52KDM4E
SCHEMBL899224 0.82 CYP2C19 (0.71) NCF1CYP2C19OPRK1
SCHEMBL5436954 0.82 CYP2C19 (0.97) NCF1CYP2C19POLBRAD52KDM4E
SCHEMBL5446310 0.82 CYP2C19 (0.71) NCF1CYP2C19OPRK1HTTRAB9A
Hydrochloric Acid SCHEMBL8686028 0.81 CYP2C19 (1.00) NCF1CYP2C19POLBRAD52KDM4E
SCHEMBL18290253 0.81 NCF1 (0.81) NCF1CYP2C19OPRK1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021081211-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2021-04-29 WO disclosed
US-9938525-B2 Compositions and methods for selective delivery of oligonucleotide molecules to cell types NLIFE THERAPEUTICS, S.L. (ES) 2018-04-10 US disclosed
US-20150315575-A1 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES PALOMO LIMITED (CY) 2015-11-05 US disclosed
EP-2621903-A1 N-HETEROARYL COMPOUNDS Intervet International B.V. (NL) 2013-08-07 EP disclosed
WO-2012041873-A1 N-HETEROARYL COMPOUNDS INTERVET INTERNATIONAL B.V. (NL) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315575-A1 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO CELL TYPES MSR1, HAVCR2, SNRPE NCF1 795/4885SLC2A1 177/4885CYP2C19 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.